tailieunhanh - Báo cáo y học: "IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. | Journal of Immune Based Therapies and Vaccines Original research BioMed Central Open Access IMP321 sLAG-3 an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults a single blind randomised controlled phase I study Chrystelle Brignone Caroline Grygar Manon Marcu Gaelle Perrin and Frédéric Triebel Address Immutep . Parc Club Orsay 2 rue Jean Rostand 91893 Orsay France Email Chrystelle Brignone - cbrignone@ Caroline Grygar - clallouet@ Manon Marcu - mmarcu@ Gaelle Perrin - gperrin@ Frédéric Triebel - ftriebel@ Corresponding author Published 29 March 2007 Received 15 December 2006 _ _ _ -r . . AAA U7Z oriorr Accepted 29 March 2007 Journal of Immune Based Therapies and Vaccines 2007 5 5 doi l 476-8518-5-5 This article is available from http content 5 1 5 2007 Brignone et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract_ Background LAG-3 CD223 is a natural high affinity ligand for MHC class II. The soluble form sLAG-3 induces maturation of monocyte-derived dendritic cells in vitro and is used as a potent Thl-like immune enhancer with many antigens in animal models. To extend this observation to human a proof of concept study was conducted with a clinical-grade sLAG-3 termed IMP32I coinjected with alum-non-absorbed recombinant hepatitis B surface antigen. Methods In a randomised single blind controlled phase I dose escalation study 48 seronegative healthy volunteers aged 18-55 years were vaccinated at 0 4 and 8 weeks by subcutaneous injection with 10 pg HBsAg mixed with saline control or with .